NCT07645586Not yet recruitingPhase 3
A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke
Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 3 Trial: MASTRE-3
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
This Phase 3 study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess whether this personalized brain stimulation approach improves functional recovery and is safe for patients after ischemic stroke.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 584 (estimated)
- First submitted
- 9 Jun 2026
- Start date
- Oct 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Stroke
- NCT number
- NCT07645586
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 584
- From Oct 2026 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant malignant tumor or severe systemic disease with life expectancy \< 90 days.
- Participation in any other interventional clinical study within 30 days before randomization, or currently enrolled in such a study.
Other illness
- Contraindications to TMS (e.g. cranial metallic foreign bodies, cardiac pacemaker, implanted drug pump, cochlear implant).
- History of epilepsy or seizure, intracranial hypertension, tumor, or other serious neurological disease.
- Evidence of acute intracranial hemorrhage, including spontaneous intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.
- Pre-stroke mRS ≥ 2.
- Severe psychiatric disorders or dementia (or other conditions) precluding informed consent or follow-up.
Other
- Midline shift or parenchymal mass effect on cranial CT or other imaging.
- CT or MRI evidence of bilateral acute cerebral infarction or infratentorial acute infarction (brainstem or cerebellum).
- Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite antihypertensive treatment.
- Pregnant or breastfeeding women, or women planning pregnancy within 90 days.
Who the study is looking for
- Age 18-80 years.
- Ischemic stroke onset within the past 14 days.
- Unilateral, supratentorial ischemic stroke confirmed by CT or MRI.
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- NIH Stroke Scale (NIHSS) total score 6-25, with item 1a ≤ 1 point, and at least one of items 5a, 5b, 6a, or 6b ≥ 2 points.
- Written informed consent signed by the patient or the patient's legally authorized representative.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.